ABSTRACT
INTRODUCTION: The association between viral infections and pulmonary exacerbations in children with cystic fibrosis (cwCF) is well established. However, the question of whether cwCF are at a higher risk of COVID-19 or its adverse consequences remains controversial. METHODS: We conducted an observational, multicenter, cross-sectional study of cwCF infected by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) between March 2020 and June 2022, (first to sixth COVID-19 pandemic waves) in Spain. The study aimed to describe patients' basal characteristics, SARS-CoV-2 clinical manifestations and outcomes, and whether there were differences across the pandemic waves. RESULTS: During study time, 351 SARS-CoV2 infections were reported among 341 cwCF. Median age was 8.5 years (range 0-17) and 51% were female. Cases were unevenly distributed across the pandemic, with most cases (82%) clustered between November 2021 and June 2022 (sixth wave, also known as Omicron Wave due to the higher prevalence of this strain in that period in Spain). Most cwCF were asymptomatic (24.8%) or presented with mild Covid-19 symptoms (72.9%). Among symptomatic, most prevalent symptoms were fever (62%) and increased cough (53%). Infection occurring along the sixth wave was the only independent risk factor for being symptomatic. Just eight cwCF needed hospital admission. No multisystem inflammatory syndrome, persisting symptoms, long-term sequelae, or deaths were reported. CONCLUSIONS: Spanish current data indicate that cwCF do not experience higher risks of SARS-CoV-2 infection nor worse health outcomes or sequelae. Changes in patients' basal characteristics, clinical courses, and outcomes were detected across waves. While the pandemic continues, a worldwide monitoring of COVID-19 in pediatric CF patients is needed.
Subject(s)
COVID-19 , Cystic Fibrosis , Humans , Child , Female , Infant, Newborn , Infant , Child, Preschool , Adolescent , Male , COVID-19/complications , COVID-19/epidemiology , SARS-CoV-2 , Cross-Sectional Studies , Spain/epidemiology , Pandemics , Cystic Fibrosis/complications , Cystic Fibrosis/epidemiology , RNA, ViralABSTRACT
Blockade of tumor necrosis factor with monoclonal antibodies, has emerged as one of the most promising therapies in some autoimmune conditions as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and Crohn's disease. They have shown effectiveness on reducing symptoms and modifying the progression of the disease. However, they disrupt the balance of inflammatory and immune responses and some risks associated with TNF-blockers have become apparent. The purpose of this article is to review the evidence about benefits and risk associated with the use of TNF-blockers in approved indications and to provide practical recommendations for its use in the management of this conditions.
Subject(s)
Immunologic Factors/therapeutic use , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Humans , Immunologic Factors/adverse effects , RiskABSTRACT
No disponible
Subject(s)
Humans , Respiratory Tract Infections/parasitology , Parasitic Diseases/epidemiology , /epidemiology , Emigration and Immigration/trends , Ascariasis/epidemiology , Strongyloidiasis/epidemiology , Paragonimiasis/epidemiology , Trichinellosis/epidemiology , Amebiasis/epidemiology , Malaria/epidemiologyABSTRACT
Fluoroquinolones-associated tendonitis and tendon rupture are well described in the literature but these are not frequently observed and related to the new agents of this group, as levofloxacin. This is probably due to the recent introduction and expansion. Although epidemiological studies are needed to know the frequency of that levofloxacin-induced tendinopathies, case-report could alert to the physicians about this possible severe adverse reaction. We present a case of bilateral Achilles tendonitis with partial spontaneous rupture probably associated to levofloxacin.
Subject(s)
Achilles Tendon/injuries , Anti-Bacterial Agents/adverse effects , Levofloxacin , Ofloxacin/adverse effects , Rupture, Spontaneous/chemically induced , Aged , Humans , MaleABSTRACT
La tendinitis y rotura de tendón es un efecto indeseado bien conocido para fluoroquinolonas que también puede producirse con las nuevos agentes de este grupo. Aunque no existen muchos casos publicados para levofloxacino, esto es probablemente debido a lo reciente de su expansión. Aunque la descripción de casos no es el mejor método de valoración de la frecuencia de este problema, puede servir para alertar a los clínicos sobre la importancia de este efecto grave cuya frecuencia consideramos que ha sido infravalorada. En esta nota clínica presentamos un caso de rotura bilateral parcial del tendón aquíleo, probablemente asociado a levofloxacino
Fluoroquinolones-associated tendonitis and tendon rupture are well described in the literature but these are not frequently observed and related to the new agents of this group, as levofloxacin. This is probably due to the recent introduction and expansion. Although epidemiological studies are needed to know the frequency of that levofloxacin-induced tendinopathies, case-report could alert to the physicians about this possible severe adverse reaction. We present a case of bilateral Achiles tendonitis with partial spontaneous rupture probably associated to levofloxacin
Subject(s)
Male , Aged , Humans , Achilles Tendon/injuries , Anti-Bacterial Agents/adverse effects , Ofloxacin/adverse effects , Rupture, Spontaneous/chemically inducedABSTRACT
La gastropatía inducida por antiinflamatorios no esteroideos es muy frecuente. Las lesiones gástricas ocasionadas por el uso de estos fármacos son subclínicas e intrascendentes en la mayoría de ocasiones, pero algunas veces los antiinflamatorios determinan la aparición de úlceras gástricas o duodenales que pueden complicarse con la aparición de hemorragia digestiva o de perforación. La prevención de estas alteraciones pasa, en primer lugar, por el uso más juicioso de los antiinflamatorios y, en segundo lugar, por la administración de algunos fármacos con finalidad protectora. Sin embargo, está plenamente demostrado que el uso de estos fármacos con fines profilácticos es necesario en pocos casos. En este artículo se revisan las recomendaciones actuales de la profilaxis farmacológica de la gastropatía inducida por antiinflamatorios no esteroideos (AU)
